Clinical Trials · NCT07087054

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

Name: Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

RecruitingPhase 3Octreotide Lanreotide

Phase: Phase 3
Recruitment status: Recruiting
Sponsor: Crinetics Pharmaceuticals Inc.
Enrollment: 141
Start date: Nov 2025
Locations: 51 sites, 9 countries
Primary endpoint: Participants will record the number of flushing per day in a daily diary to assess the efficacy of paltusotine vs placebo in reducing flushing episodes.

View Octreotide compound reference